Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral EP262 Clear all
Terminated Phase 2 Interventional Results available

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

NCT06077773
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Oral EP262, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 8, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Oral EP262, Placebo
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Miami Lakes, Florida • Plainfield, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 8, 2026, 8:01 PM EDT
Completed Phase 1 Interventional

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Oral EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 8, 2026, 8:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

NCT06645704
View directory record Official record
Conditions
Healthy Participants
Interventions
EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 8, 2026, 8:01 PM EDT